This study aimed to clarify the beneficial effect and the clinical application value of Paxlovid
in the treatment of coronavirus disease‐19 (COVID‐19) through a systematic review …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral
shedding, lowering transmission risks from treated patients. By fitting a mathematical model …

Introduction At present, there are some randomized controlled trials (RCTs) of oral small
molecule drugs. The purpose of this study was to evaluate the efficacy and safety of oral …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

Background Paxlovid is recognized as an effective medication in preventing the progression
of coronavirus disease of 2019 (COVID-19) to severe form in adults; however, its efficacy …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Coronavirus infection is a pandemic threat and the most dangerous disease of the 21 st
century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for …